–
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Recovery · Next-Gen BPC
Pentadeca Arginate (PDA)
Released: Last reviewed:
Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157.
Pentadeca Arginate (PDA) at a glance
Pentadeca Arginate is a stabilized analog of BPC-157 with an arginate salt formulation, marketed as a longer-acting and more bioavailable alternative to standard BPC-157. Mechanism: BPC-157 analog (arginate salt). Typical route: Subcutaneous, oral. FDA status: Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal
Drug classBPC-157 analog (arginate salt)
Half-lifeLonger than standard BPC-157
RouteSubcutaneous, oral
Common dosing250-500 mcg/day
FDA statusNot approved
Available throughSee the dated FDA status notice above
Mechanism of action
PDA shares BPC-157's proposed mechanism of action: promoting angiogenesis, modulating nitric oxide pathways, and accelerating soft-tissue repair. The arginate stabilization is intended to extend half-life and improve oral and subcutaneous bioavailability.
Dosing reference
Subcutaneous: 250-500 mcg once or twice daily, typically near the injury site. Oral: 500 mcg-1 mg daily for gut-related applications. Cycles are commonly 4-6 weeks on, with re-evaluation.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Dispensed by peptide compounding pharmacies. Clinical-trial evidence is limited compared with the underlying BPC-157 literature; most of the evidence base is preclinical or anecdotal.
U.S. telehealth providers that work with Pentadeca Arginate (PDA)
–
70/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
85/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →–
71/100May 2026 review (v3.0 rubric); v4.1 re-score pending
Offering and price for this peptide not verified in the October 15, 2026 update.
Read review →Related recovery peptides
Frequently asked questions about Pentadeca Arginate (PDA)
How is PDA different from BPC-157?
Pentadeca Arginate is the same core 15-amino-acid sequence as BPC-157 with an arginate-salt modification intended to improve stability and bioavailability. In practice, claimed advantages over BPC-157 vary between manufacturers.
Is PDA safer than BPC-157?
There is no robust head-to-head safety data. Both are not FDA-approved; safety profiles in published preclinical work are similar.
References
- Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26967018
- Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.